
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems Inc. demonstrated robust financial performance, with overall revenue increasing by 13.2% and the Cardiovascular segment experiencing an 11.0% growth, reflecting strong demand for medical devices that aid in diagnosing and treating various cardiovascular diseases. The Endoscopy segment significantly outperformed expectations, posting an impressive 81.0% revenue increase largely attributed to recent mergers and acquisitions. Additionally, the company has raised its earnings guidance for FY/25 due to a more favorable tariff environment and stronger-than-anticipated results in the first half of the fiscal year, highlighting confidence in continued financial performance.
Bears say
Merit Medical Systems Inc. is experiencing a concerning downturn in its China business, which declined 6% year-over-year in the second quarter, attributed to ongoing macroeconomic softness that has persisted over two quarters. The company also significantly reduced its revenue guidance for Wrapsody from an expected $7-9 million to $2-4 million, indicating potential challenges in future revenue streams. Furthermore, while the gross margin reported at 48.2% exceeded estimates, the cardiovascular segment's peripheral intervention revenue fell short of expectations, totaling $142.8 million against an anticipated $145.5 million, highlighting persistent operational weaknesses.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares